Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658271 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL658272 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL29434936 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL658927 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL659851 | 0.95 | MDM2 (0.91) | MDM2TP53 | |
| SCHEMBL659850 | 0.95 | MDM2 (0.91) | MDM2TP53 | |
| SCHEMBL660812 | 0.95 | MDM2 (0.90) | MDM2TP53 | |
| SCHEMBL660813 | 0.95 | MDM2 (0.90) | MDM2TP53 | |
| SCHEMBL660458 | 0.94 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL658747 | 0.94 | MDM2 (0.90) | MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121586709-A | Checkpoint kinase 1 (CHK 1) inhibitor crystal forms and uses thereof | 无界生物公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4688770-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITOR CRYSTALLINE FORM AND USES THEREOF | Boundless Bio, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4626433-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS COMBINATIONS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4532486-A1 | PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119546588-A | Pyridine checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024211270-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITOR CRYSTALLINE FORM AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024211271-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITOR PHARMACEUTICAL COMPOSITION | BOUNDLESS BIO, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024196923-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | BOUNDLESS BIO, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024118596-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS COMBINATIONS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024118564-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4347582-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117715905-A | Checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023230477-A1 | PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022251502-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MDM2 276/4885TP53 30/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | MDM2 276/4885TP53 30/4885 |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MDM2 276/4885TP53 30/4885 |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, RAD1, CHEK2 | MDM2 772/4885TP53 163/4885 |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | MDM2 517/4885TP53 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.